drugset / Trial / NCT01188811
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Phase 2/3
Completed
54 enrolled
VA Office of Research and Development
Oregon Health and Science University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.
Timeline
- Start
- 2010-10
- Primary completion
- 2015-08
- Completion
- 2015-08
Publications
- Loy BD, Fling BW, Horak FB, Bourdette DN, Spain RI. Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. Complement Ther Med. 2018 Dec;41:169-174. doi: 10.1016/j.ctim.2018.09.006. Epub 2018 Sep 22.
- Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, Cameron M, Kim E, Horak F, Simon J, Bourdette D. Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e374. doi: 10.1212/NXI.0000000000000374. eCollection 2017 Sep.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | alpha-lipoic acid | Small molecule | 1200 mg | Oral |